Update: see some articles from the event
Uncertainty identified during health technology assessment of innovative new medicines is increasingly being addressed through a managed entry agreement / risk-sharing agreement between the manufacturer and the payer. Over time, there has been a proliferation of managed entry schemes focusing, among other things, on price, utilisation and outcomes.
The Medical Technology Research Group (MTRG) at LSE Health hosted a one-day summit on Risk Sharing and Managed Entry Agreements (MEAs) in February 2014. Speakers debated the latest developments, future prospects and policy options.
The summit was sponsored by Ernst and Young, with media partner The Financial Times.
Programme Directors: Panos Kanavos, PhD and Alessandra Ferrario, MSc, MTRG and LSE Health, London School of Economics and Political Science
Date: 14 February 2014, 9am-5pm
Venue: The Royal College of Surgeons, Lecture Theatre Two, 35-43 Lincoln's Inn Fields, London WC2A 3PE, UK
Speakers: Speakers were drawn from national competent authorities on pricing, reimbursement and HTA, pharmaceutical manufacturers, international organisations, patient representative organisations and academia